BioSpace News Archive

For the sixth consecutive year, Astellas has achieved a perfect score on the Human Rights Campaign Foundation’s annual Corporate Equality Index.

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced preliminary unaudited revenue for the full year 2019.

The Board of Directors of Progenics Pharmaceuticals, Inc., an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, issued the following letter to shareholders

Vyaire Medical, Inc. announced that its Board of Directors has appointed Gaurav Agarwal as Chief Executive Officer, effective immediately.

Washington, DC-based healthcare technology startup Socially Determined announced today that it has closed its Series A investment round, raising a total of $11.1M.

Ferrotec Corporation, the US subsidiary of Ferrotec Holdings Corp., a global supplier of materials, components, and precision system solutions and the leading manufacturer of magnetic liquids, announced the PBG-series of polyethylene glycol based ferrofluids for bio-medical and other applications.

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Jay Skyler, MD to its Scientific Advisory Board.

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the initiation of a first-in-human Phase 1 trial evaluating its second generation pipeline compound, SBT-272, in healthy subjects.

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, provided a corporate update and outlook for calendar year 2020.

Onkos Surgical, Inc. a leader in the field of musculoskeletal oncology and personalized orthopaedics announced today a multi-year agreement with Integrum AB (INTEG B: Nasdaq First North exchange).